Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV Cohort Study

Antiviral Therapy

Volumn 10, Issue 1, 2005, Pages 73-81

  Young, Jim ^a   Rickenbach, Martin ^b   Weber, Rainer ^c   Furrer, Hansjakob ^d   Bernasconi, Enos ^e   Hirschel, Bernard ^f   Tarr, Philip E ^b   Vernazza, Pietro ^g   Battegay, Manuel ^h   Bucher, Heiner C ^a,h  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CD4 ANTIGEN; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; GLUCOSE; INDINAVIR; LACTIC ACID; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY FAT; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SWITZERLAND; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS INFECTION; VIRUS LOAD; WAIST CIRCUMFERENCE; WAIST HIP RATIO; ADIPOSE TISSUE; DRUG EFFECT; MIDDLE AGED; PATHOLOGY;

ADIPOSE TISSUE; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; STAVUDINE; SWITZERLAND;

EID: 20044376916     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ & Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58.
2. Safrin S & Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999;13:2493-2505.
3. Carr A, Emery S, Law M, Puls R, Lundgren JD & Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361:726-735.
4. Oette M, Juretzko P, Kroidl A, Sagir A, Wettstein M, Siegrist J & Haussinger D. Lipodystrophy syndrome and self-assessment of well-being and physical appearance in HIV-positive patients. AIDS Patient Care & STDs 2002; 16:413-417.
5. Duran S, Saves M, Spire B, Cailleton V, Sobel A, Carrieri P, Salmon D, Moatti JP & Leport C. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2001; 15:2441-2444.
6. Friis-Moller N, Sabin CA, Weber R, d'Arminio MA, El Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN & Lundgren JD. Combination antiretroviral therapy and the risk of myocardial infarction. New England Journal of Medicine 2003; 349:1993-2003.
7. Galli M, Ridolfo AL, Adorni F, Gervasoni C, Ravasio L, Corsico L, Gianelli E, Piazza M, Vaccarezza M, d'Arminio MA & Moroni M. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. Journal of Acquired Immune Deficiency Syndromes 2002; 29:21-31.
8. Mallal SA, John M, Moore CB, James IR & McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14:1309-1316.
9. Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, Bianchi L, Conget I, Blanch J, Phillips A & Gatell JM. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357:592-598.
10. Martinez E, Bailey L, Milinkovic A, Blanco JL, Lonca M, Laguno M, Leon A, Mallolas J, Phillips AN & Gatell JM. A prospective cohort study on the risk of lipodystrophy in HIV-1 infected patients with highly active antiretroviral therapy not containing protease inhibitors. Antiviral Therapy 2003; 8:L80.
11. Drechsler H & Powderly WG. Switching effective antiretroviral therapy: a review. Clinical Infectious Diseases 2002; 35:1219-1230.
12. Mauss S, Corzillius M, Wolf E, Schwenk A, Adam A, Jaeger H, Knechten H, Goelz J & Goetzenich A. Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Medicine 2002; 3:49-55.
13. Heath KV, Hogg RS, Singer J, Chan KJ, O'Shaughnessy MV & Montaner JS. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort. Journal of Acquired Immune Deficiency Syndromes 2002; 30:440-447.
14. Kotler DP, Rosenbaum K, Wang J & Pierson RN. Studies of body composition and fat distribution in HIV-infected and control subjects. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 1999; 20:228-237.
15. Boufassa F, Dulioust A, Lascaux AS, Meyer L, Boue F, Delfraissy JF, Sobel A & Goujard C. Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response. HIV Clinical Trials 2001;2:339-345.
16. Lichtenstein KA, Delaney KM, Armon C, Ward DJ, Moorman AC, Wood KC & Holmberg SD. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. Journal of Acquired Immune Deficiency Syndromes 2003; 32:48-56.
17. Jain RG, Furfine ES, Pedneault L, White AJ & Lenhard JM. Metabolic complications associated with antiretroviral therapy. Antiviral Research 2001; 51:151-177.
18. Carter VM, Hoy JF, Bailey M, Colman PG, Nyulasi I & Mijch AM. The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Medicine 2001; 2:174-180.
19. Kalbfleisch JD & Prentice RL. The Statistical Analysis of Failure Time Data. 1980. New York: Wiley.
20. Grunfeld C & Tien P. Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome. Clinical Infectious Diseases 2003; 37(Suppl 2):S43-S46.
21. Miller J, Carr A, Emery S, Law M, Mallal S, Baker D, Smith D, Kaldor J & Cooper DA. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Medicine 2003; 4:293-301.
22. Brinkman K, Smeitink JA, Romijn JA & Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354:1112-1115.
23. Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, Wong H, Harris M, Harrigan PR, O'Shaughnessy MV & Montaner JS. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. New England journal of Medicine 2002; 346:811-820.
24. Anderson PL, Kakuda TN & Lichtenstein KA. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clinical Infectious Diseases 2004; 38:743-753.
25. Bernasconi E, Boubaker K, Junghans C, Flepp M, Furrer HJ, Haensel A, Hirschel B, Boggian K, Chave JP, Opravil M, Weber R, Rickenbach M & Telenti A. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. Journal of Acquired Immune Deficiency Syndromes 2002; 31:50-55.
26. Hanvanich M, Prasanthai V, Riengchan P, Arunyingmongkol K, Intalapaporn P, Hiransuthikul N, Suankratay C & Kulwichit W. Reduction of D4T dosage improves lipoatrophy without virologic failure. 2nd International AIDS Society Conference on HIV Pathogenesis & Treatment. 13-17 July 2003, Paris, France. Abstract 749.
27. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ & Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
28. Kosmiski L, Kuritzkes D, Hamilton J, Sharp T, Lichtenstien K, Hill J & Eckel R. Fat distribution is altered in HIV-infected men without clinical evidence of the HIV lipodystrophy syndrome. HIV Medicine 2003; 4:235-240.
29. Kotler DP. The epidemiology and pathogenesis of lipodystrophy in HIV disease: an update. PRN Notebook 2000;5:9-13.
30. Ioannidis JP, Trikalinos TA, Law M & Carr A. HIV lipodystrophy case definition using artificial neural network modelling. Antiviral Therapy 2003; 8:435-441.
31. Joly V, Flandre P, Meiffredy V, Leturque N, Harel M, Aboulker JP & Yeni P. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002; 16:2447-2454.
32. Amin J, Moore A, Carr A, French MA, Law M, Emery S & Cooper DA. Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2. HIV Clinical Trials 2003; 4:252-261.
33. Becher F, Pruvost AG, Schlemmer DD, Creminon CA, Goujard CM, Delfraissy JF, Benech HC & Grassi JJ. Significant levels of intracellular stavudine triphosphate are found in HIV-infected zidovudine-treated patients. AIDS 2003; 17:555-561.
34. Rickenbach M, Keiser O, Taffé P & Francioli P. [Swiss HIV Cohort Study.] Médecine & Hygiène 2003; 61:719-723. French.